Impressed with the upcoming HemoDefend trial. "We plan to utilize the current manufacturing facility, leveraging existing assets and infrastructure, to produce HemoDefend clinical devices for the planned HemoDefend U.S. pivotal trial to start in late 2018-early 2019." If they are converting the present manufacturing facility to entirely producing HemoDefend for the trial, they are looking at easily 10's of thousands of bags for the study. <br /> <br /> "More than 10,000 units of fresh frozen plasma are administered each day, or more than 3.6 million units per year, in the United States alone. With the exception of Type AB plasma, plasma typically requires blood-type matching with the patient to prevent incompatibilities and reduce the risk of major transfusion reactions. Because Type AB plasma lacks blood type-specific antibodies, it is called ‘universal plasma’ and can be readily administered to patients in emergency situations, making logistics fairly straightforward for both military and civilian applications."